PR Newswire

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

"We are thrilled to bring this game-changing platform to the market as it solves a huge unmet need in biomarker analysis for an automated solution for high sensitivity, multiplexed detection of ...
abc27

Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

FREMONT, Calif., Dec. 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in ...
The Scientist

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease

The Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator (DxA) today announced a $10M investment in Alamar Biosciences, Inc. This landmark investment, the largest in DxA history, ...
FOX8 Cleveland

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

FREMONT, Calif., Jan. 4, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the ARGO ...